Results 61 to 70 of about 280,456 (250)
Mechanism, clinical consequences, and management of dyslipidemia in children with nephrotic syndrome [PDF]
Childhood Kidney Diseases, 2022 Dyslipidemia in nephrotic syndrome (NS) is often characterized by marked increases in the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and other lipoproteins, such as very low-density lipoprotein, intermediate-density ...
Hee Sun Baek
doaj +1 more source
Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia [PDF]
, 2014 The microsomal triglyceride transfer protein (MTP) inhibitor lomitapide is a licenced adjunct to a low-fat diet and other lipid-lowering medication, with or without low-density lipoprotein apheresis, for the treatment of adults with homozygous familial ...
AVERNA, Maurizio, Blom, DJ, Cuchel, M
core +1 more source
Pregnancy in a Woman with Homozygous Familial Hypercholesterolemia Not on Low-Density Lipoprotein Apheresis [PDF]
, 2014 Pregnancy in women with homozygous familial hypercholesterolemia (FH) has been rarely reported and might pose risks on the mother and her fetus. Although most reported cases remained on low-density lipoprotein (LDL) apheresis, there are no clear ...
Fahed, Akl C., Nassar, Anwar H.
core +1 more source
LDL‐aférese no tratamento de hipercolesterolemia familiar: experiência do Hospital Santo António
Revista Portuguesa de Cardiologia, 2015 Resumo: Introdução: A hipercolesterolemia manifestada pelos níveis elevados de colesterol das lipoproteínas de baixa densidade constitui um fator de risco major para o desenvolvimento e progressão da doença aterosclerótica prematura.A adsorção direta de
Isabel Palma +8 more
doaj +1 more source
LDL-Apheresis: Technical and Clinical Aspects
The Scientific World Journal, 2012 The prognosis of patients suffering from severe hyperlipidemia, sometimes combined with elevated lipoprotein (a) levels, and coronary heart disease refractory to diet and lipid-lowering drugs is poor. For such patients, regular treatment with low-density
Rolf Bambauer +4 more
doaj +1 more source
Journal of Lipid Research, 1990 Low density lipoproteins (LDL) have the potential to serve as cell specific drug carriers. The LDL may be derived in large quantities from LDL-apheresis procedures.
HW Schultis +3 more
doaj +1 more source
Российский кардиологический журналThe article presents the up-to-date information on the effect of lipoprotein apheresis (LA) on atherosclerotic lesions. Some studies using modern diagnostic imaging techniques (such as intravascular ultrasound or magnetic resonance imaging) have clearly ...
Ulrich Julius +2 more
doaj +1 more source
LIPOPROTEIN APHERESIS: YESTERDAY, TODAY, TOMORROW. REVIEW
Российский кардиологический журнал, 2018 The first attempts to treat patients with homozygous familial hypercholesterolemia (HCH) were performed in the 60ies and 70ies using a total plasma exchange. Later on, more specific lipoprotein apheresis (LA) methods have been developed – the replacement
U. Julius, S. Tselmin, S. R. Bornstein
doaj +1 more source
Familial hypercholesterolemia: a systematic review of guidelines on genetic testing and patient management [PDF]
, 2017 BACKGROUND: Familial hypercholesterolemia (FH) is an autosomal-dominant hereditary disorder of lipid metabolism that causes lifelong exposure to increased LDL levels resulting in premature coronary heart disease and, if untreated, death.
Baccolini, Valentina +6 more
core +2 more sources
HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. [PDF]
PLoS ONE, 2014 BACKGROUND:Pentraxin 3 (PTX3), a key component of the humoral arm of innate immunity, is secreted by vascular cells in response to injury, possibly aiming at tuning arterial activation associated with vascular damage.
Michela Zanetti +11 more
doaj +1 more source